Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference

  • At the Needham Healthcare Conference, Phathom Pharmaceuticals Inc PHAT says that licensor Takeda Pharmaceutical Co Ltd TAK reported Takecab (vonoprazan) Q4 FY21 sales of $221 million and $900 million in FY21.
  • Phathom estimates that around 30% is from erosive esophagitis (EE), approximately 60% is from gastroesophageal reflux disease (GERD)/other, and less than 10% is from H. pylori.
  • PHAT is positioning vonoprazan as an acid blocker, the analysts write.
  • Related: Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation.
  • The Company submitted an FDA marketing application in March. Needham anticipates the acceptance decision in mid-May 2022. PHAT guiding expects a broad label across all EE Grades. 
  • "Our peaks sales estimate in H. pylori is ~$115 million," writes Needham.
  • PHAT plans to launch in H. pylori with 65 sales reps and expand to 330 representatives, targeting 46K physicians for EE. Payor discussions are ongoing. 
  • Dexilant is a good pricing comp ($10.28), but PHAT believes it can command a premium based on superiority and different MoA. 
  • PHAT reported positive Phase 2 results in February. Phase 3 trial ongoing with enrollment to complete in 2H 2022 and results in 2023 (unch). 
  • PHAT will meet with FDA following Phase 3 trial results to finalize the details/design Phase 3 on-demand dosing trial, which is likely to start in 2024.
  • Price Action: PHAT shares are up 1.85% at $14.61 during the market session on the last check Wednesday.

Posted In: BriefsAnalyst ColorBiotechNewsHealth CareSmall CapAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.